Posted on 04/22/2020 3:54:47 PM PDT by nickcarraway
Nutrition, Metabolism & Cardiovascular Diseases Lima A, Ferin R, Fontes A, et al.
This study was intended to assess whether cysteine is a better prognosticator of coronary artery disease than conventional homocysteine in high-risk subjects under preventive medication. Researchers enrolled a total of 174 individuals with symptomatic coronary artery disease (CAD) (age 56±9y; 68% men) who submitted to coronary angiography were split into 2 groups: one formed by CAD patients (≥50% stenosis in at least one major coronary vessel) and the other by non-CAD patients (<50% stenosis). Via RP-HPLC/FLD, Plasma and erythrocyte aminothiol profiles were assessed. Compared with non-CAD group, CAD patients significantly showed both higher concentrations of plasma Cys and hypercysteinemia prevalence. Compared with hyperhomocysteinemia, hypercysteinemia revealed to be a better predictor of CAD. Furthermore, plasma Cys exhibited to be a feasible biomarker for CAD both in primary and secondary preventions, seeming to resist better than Hcy to oral medication therapy.
Now we may have an even better test. Will it matter?
BTTT MDLinx
Interesting. It would seem taking NAC could be a problem.
It will, absolutely, at least it will once there is a patented cysteine reducing drug with suitable kickbacks.
Right now doctors have their patients on damaging medication unnecessarily.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.